Vosslamber S - Search Results

1

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.

Vosslamber S, van Baarsen LG, Verweij CL. Vosslamber S, et al. Pharmacogenomics. 2009 Jan;10(1):97-108. doi: 10.2217/14622416.10.1.97. Pharmacogenomics. 2009. PMID: 19102719 Review.

2

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.

Vosslamber S, van der Voort LF, van den Elskamp IJ, Heijmans R, Aubin C, Uitdehaag BM, Crusius JB, van der Pouw Kraan TC, Comabella M, Montalban X, Hafler DA, De Jager PL, Killestein J, Polman CH, Verweij CL. Vosslamber S, et al. Genes Immun. 2011 Sep;12(6):466-72. doi: 10.1038/gene.2011.18. Epub 2011 Apr 7. Genes Immun. 2011. PMID: 21471993

3

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL. van Baarsen LG, et al. Among authors: vosslamber s. PLoS One. 2008 Apr 2;3(4):e1927. doi: 10.1371/journal.pone.0001927. PLoS One. 2008. PMID: 18382694 Free PMC article.

4

New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine.

Verweij CL, Vosslamber S. Verweij CL, et al. Among authors: vosslamber s. Discov Med. 2011 Sep;12(64):229-36. Discov Med. 2011. PMID: 21955850 Free article. Review.

5

Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy.

Verweij CL, Vosslamber S. Verweij CL, et al. Among authors: vosslamber s. Discov Med. 2013 Jan;15(80):51-60. Discov Med. 2013. PMID: 23375014 Free article. Review.

6

Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis.

Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Chitnis S, Polman C, Vosslamber S, Verweij CL, Olsen NJ, Aune TM. Tossberg JT, et al. Among authors: vosslamber s. Genes Immun. 2012 Feb;13(2):146-54. doi: 10.1038/gene.2011.66. Epub 2011 Sep 22. Genes Immun. 2012. PMID: 21938015 Free PMC article.

7

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL. Vosslamber S, et al. Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27. Ann Rheum Dis. 2011. PMID: 21444302 Clinical Trial.

8

Combining DNA-microarray data in systemic lupus erythematosus.

Verweij CL, Vosslamber S. Verweij CL, et al. Among authors: vosslamber s. Genome Med. 2011 May 31;3(5):30. doi: 10.1186/gm246. Genome Med. 2011. PMID: 21639954 Free PMC article.

9

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE. Raterman HG, et al. Among authors: vosslamber s. Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819. Arthritis Res Ther. 2012. PMID: 22540992 Free PMC article.

10

The type I IFN signature as a biomarker of preclinical rheumatoid arthritis.

Lübbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, Rantapää-Dahlqvist S, Verweij CL. Lübbers J, et al. Among authors: vosslamber s. Ann Rheum Dis. 2013 May;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753. Epub 2013 Feb 23. Ann Rheum Dis. 2013. PMID: 23434571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page